期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 19, 期 10, 页码 1235-1243出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2010.514262
关键词
antiangiogenic agent; prostate cancer; quinoline-3-carboxamide; tasquinimod
资金
- NCI NIH HHS [P50 CA058236] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER
Importance of the field: Prostate cancer is the mostly commonly diagnosed non-skin cancer in males. The culmination of the last 70 years of clinical drug development has documented that androgen ablation plus taxane-based systemic chemotherapy enhances survival, but is not curative, in metastatic prostate cancer. To effect curative therapy, additional drugs must be developed that enhance the response when combined with androgen ablation/taxane therapy. Areas covered in this review: The history of the discovery and development of tasquinimod as a second-generation oral quinoline-3-carboxamide analogue for prostate cancer will be presented. What the reader will gain: The mechanism for such anticancer efficacy is via tasquinimod's ability to inhibit the 'angiogenic switch' within cancer sites required for their continuous lethal growth. Take home message: Tasquinimod is a novel inhibitor of tumor angiogenesis that enhances the therapeutic anticancer response when combined with other standard-of-care modalities (radiation, androgen ablation, and/or taxane-based chemotherapies) in experimental animal models, but does not inhibit normal wound healing. It has successfully completed clinical Phase II testing in humans and will shortly enter registration Phase III evaluation for the treatment of metastatic prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据